DFLC <50 mg/L shows prognostic value with respect to overall and renal survival in multivariate Cox regression analyses, including age, Mayo 2004 stage, and renal stage
| Criterion . | Overall survival (n = 717 with 358 events) . | Renal survival (n = 420 with 111 events) . | ||
|---|---|---|---|---|
| HR (95% CI) . | P* . | HR (95% CI) . | P* . | |
| Age (1-y increase) | 1.01 (0.99-1.02) | .340 | 1.02 (1.00-1.05) | .060 |
| dFLC <50 mg/L (yes vs no) | 0.50 (0.32-0.79) | .003 | 0.56 (0.35-0.91) | .020 |
| Mayo stage II vs I | 1.73 (1.14-2.62) | .010 | Not included | |
| Mayo stage III vs I | 3.71 (2.46-5.61) | <.001 | Not included | |
| Renal stage II vs I | Not included | 10.15 (3.67-28.10) | <.001 | |
| Renal stage III vs I | Not included | 38.09 (13.50-107.47) | <.001 | |
| Criterion . | Overall survival (n = 717 with 358 events) . | Renal survival (n = 420 with 111 events) . | ||
|---|---|---|---|---|
| HR (95% CI) . | P* . | HR (95% CI) . | P* . | |
| Age (1-y increase) | 1.01 (0.99-1.02) | .340 | 1.02 (1.00-1.05) | .060 |
| dFLC <50 mg/L (yes vs no) | 0.50 (0.32-0.79) | .003 | 0.56 (0.35-0.91) | .020 |
| Mayo stage II vs I | 1.73 (1.14-2.62) | .010 | Not included | |
| Mayo stage III vs I | 3.71 (2.46-5.61) | <.001 | Not included | |
| Renal stage II vs I | Not included | 10.15 (3.67-28.10) | <.001 | |
| Renal stage III vs I | Not included | 38.09 (13.50-107.47) | <.001 | |
For multivariate analysis of overall survival, all patients were analyzed. For multivariate analysis of renal survival, only patients with kidney involvement were included. Both analyses were stratified by therapy. Covariates were age, dFLC <50 mg/L, Mayo 2004 stage (only overall survival), and renal stage (only renal survival). HRs are shown with corresponding 95% CIs.
P values in italics indicate statistical significance.